NIH Funding Opportunities (Notices, PA, RFA)

Subscribe to NIH Funding Opportunities (Notices, PA, RFA) feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 1 hour 44 min ago

Catalyst Award In Diabetes, Endocrinology and Metabolic Diseases (DP1 Clinical Trial Not Allowed)

Wed, 2019-07-31 12:24
Funding Opportunity RFA-DK-19-014 from the NIH Guide for Grants and Contracts. The Catalyst Award in Diabetes, Endocrinology and Metabolic Diseases (Catalyst-DEMD) is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering andtransformational studies in DEMD topic areas. Applications should be focused on major scientific challenges, and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases. To be considered responsive to this initiative, the proposed research should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigators research program or elsewhere.

Notice of Clarification for NOT-MH-19-033, "Notice of Data Sharing Policy for the National Institute of Mental Health"

Wed, 2019-07-31 12:09
Notice NOT-MH-19-041 from the NIH Guide for Grants and Contracts

Request for Information: Input into the National Institute of Neurological Disorders and Stroke Strategic Planning Process

Wed, 2019-07-31 11:57
Notice NOT-NS-19-079 from the NIH Guide for Grants and Contracts

Updates for PAR-16-098 "Cooperative Research Agreements Related to World Trade Center Health Program (U01)"

Wed, 2019-07-31 11:52
Notice NOT-OH-19-006 from the NIH Guide for Grants and Contracts

Notice of Webinar for RFA-AG-20-020 "Nathan Shock Centers of Excellence in Basic Biology of Aging (P30 Clinical Trial Not Allowed)"

Wed, 2019-07-31 11:49
Notice NOT-AG-19-036 from the NIH Guide for Grants and Contracts

Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (R21 Clinical Trial Optional)

Wed, 2019-07-31 11:25
Funding Opportunity PAR-19-326 from the NIH Guide for Grants and Contracts. Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (LMICs) seeks to stimulate new and impactful research towards the development of stigma reduction interventions leading to better outcomes for the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS (PLWH) in LMICs.

Revision Applications to Support the Application of Informatics Technology for Cancer Research (U24 Clinical Trials Optional)

Wed, 2019-07-31 11:02
Funding Opportunity RFA-CA-19-063 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U24 research projects proposing to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery.

Revision Applications to Support the Application of Informatics Technology for Cancer Research (R01 Clinical Trials Optional)

Wed, 2019-07-31 11:02
Funding Opportunity RFA-CA-19-062 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects proposing to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery.

Revision Applications to Support the Application of Informatics Technology for Cancer Research (U01 Clinical Trials Optional)

Wed, 2019-07-31 11:02
Funding Opportunity RFA-CA-19-061 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects proposing to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery.

US Children with Perinatal HIV who were Born Internationally (R01 Clinical Trial Optional)

Wed, 2019-07-31 09:48
Funding Opportunity RFA-HD-20-006 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to stimulate research on an area of emerging public health significance and improve understanding of the natural history, epidemiology, diagnosis and management of HIV and co-morbid conditions among US children who were born internationally and acquired HIV from their mothers.

Palliative Care in Home and Community Settings (R01 Clinical Trial Optional)

Wed, 2019-07-31 09:34
Funding Opportunity PAR-19-321 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in this FOA refer to the place where an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care.

Palliative Care in Home and Community Settings (R21 Clinical Trial Optional)

Wed, 2019-07-31 09:32
Funding Opportunity PAR-19-320 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in this FOA refer to the place where an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care.

Participant Engagement and Cancer Genome Sequencing (PE-CGS): Research Centers (U2C Clinical Trial Optional)

Tue, 2019-07-30 13:47
Funding Opportunity RFA-CA-19-045 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSMInitiative that is intended to accelerate cancer research. Specifically, this FOA falls under a scientific priority designated by the Blue Ribbon Panel (BRP) as Recommendation A "Establish a Network for Direct Patient Engagement". The National Cancer Institute (NCI) intends to support the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. The PE-CGS Network will include: Several U2C Research Centers (to be supported under this FOA); and One U24 Coordinating Center (to be supported under companion RFA-CA-19-046). The overall purpose of the PE-CGS Network is twofold: To promote and support research on direct participant* engagement approaches; and Use such approaches for rigorous cancer genome sequencing projects addressing important knowledge gaps in the genomic characterizations of tumors in areas such as, but not limited to: Rare cancers or rare cancer subsets; Highly lethal cancers; Cancers with an early age of onset; Cancers with high disparities in incidence and/or mortality; or Cancers in understudied populations. *Note: For this FOA, study participant denotes cancer patients and/or post-treatment cancer survivors. Each PE-CGS U2C Research Center to be proposed in response to this FOA must consist of the following components: Administrative Core Participant Engagement Unit; Genome Characterization Unit; and Engagement Optimization Unit. In addition to conducting individual projects, PE-CGS U2C Research Centers will be expected to operate as a collaborative network. Various trans-network activities will be facilitated by the PE-CGS Network Coordinating Center (U24).

Participant Engagement and Cancer Genome Sequencing (PE-CGS): Coordinating Center (U24 Clinical Trial Not Allowed)

Tue, 2019-07-30 13:47
Funding Opportunity RFA-CA-19-046 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSMInitiative that is intended to accelerate cancer research. Specifically, this FOA falls under a scientific priority designated by the Blue Ribbon Panel (BRP) as Recommendation A "Establish a Network for Direct Patient Engagement". The National Cancer Institute (NCI) intends to support the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. The PE-CGS Network will include: Several U2C Research Centers (to be supported under companion RFA-CA-19-045); and One U24 Coordinating Center (to be supported under this FOA). The overall purpose of the PE-CGS Network is twofold: To promote and support research on direct participant* engagement approaches; and Use such approaches for rigorous cancer genome sequencing projects addressing important knowledge gaps in the genomic characterizations of tumors in areas such as, but not limited to: Rare cancers or rare cancer subsets; Highly lethal cancers; Cancers with an early age of onset; Cancers with high disparities in incidence and/or mortality; or Cancers in understudied populations. *Note: For this FOA, study participant denotes cancer patients and/or post-treatment cancer survivors. PE-CGS U2C Research Centers, together with the PE-CGS U24 Coordinating Center, will form a collaborative Network. The PE-CGS U24 Coordinating Center will have three major areas of responsibility: (1) Network Coordination; (2) Network Outreach and Promotion; and (3) Network Best Practices.

Notice of Change to PAR-18-581 "Emotional Function in Normal Aging and/or MCI and AD/ADRD (R01 Clinical Trial Optional)"

Tue, 2019-07-30 13:30
Notice NOT-AG-19-026 from the NIH Guide for Grants and Contracts

Notice of Change to PAR-18-582 "Emotional Function in Normal Aging and/or MCI and AD/ADRD (R21 Clinical Trial Not Allowed)"

Tue, 2019-07-30 13:20
Notice NOT-AG-19-025 from the NIH Guide for Grants and Contracts

Pages